Advisors

Drug development.
Dr. Wright has over 30 years of experience in biotech and pharmaceuticals, having played a key role in the development of Epidiolex, the first FDA-approved prescription cannabidiol treatment for seizures, and the approval of a second-generation 5-lipoxygenase inhibitor. From 2005 to 2018, he served as Chief Medical Officer and board member at GW Pharmaceuticals. Previously, he was Senior VP of Clinical Research at Ipsen and Neuroscience Venture Head at Abbott Laboratories. A prolific researcher with over 100 publications, Dr. Wright is also a visiting professor at the University of Reading.

Regulatory.
Ms. Ashley is the Former Acting Assistant Administrator of the Drug Enforcement Administration, Diversion Control Division. She is a leading expert in pharmaceutical regulatory compliance with over 30 years of experience combatting the diversion of controlled substances as a DEA senior executive. During her tenure at DEA, Ms. Ashley served as Acting Assistant Administrator of the Diversion Control Division, overseeing 1,700 employees in investigating and preventing drug diversion. She played a key role in shaping regulations, creating programs, and collaborating with government agencies, law enforcement, and private organizations. She holds a bachelor’s degree from Wayne State University and a master’s degree from Northwestern University.

Regulatory.
Ms. Baylor-Henry has spent her career in medical regulatory affairs. Her roles have included Worldwide Vice President of Regulatory Affairs for Medical Devices & Diagnostics at Johnson & Johnson, Vice President of Medical & Regulatory Affairs for McNeil Consumer Healthcare, as well as senior roles at the U.S. Food and Drug Administration, including National Health Fraud Coordinator and Director of the Division of Drug Marketing, Advertising, and Communications.

Cannabinoid policy.
During his 35-year career at the National Institute on Drug Abuse (NIDA), Dr. Gust had key responsibilities for cannabis research issues, including overseeing the production of research-grade marijuana, and developing and coordinating procedures and policies related to research on potential medical applications of marijuana for the National Institutes of Health (NIH) and U.S. Department of Health and Human Services.  He also spent more than 20 years leading NIDA’s International Program which focused on expanding research globally, building a strong network of international researchers, and exchanging and communicating scientific information.

Cannabinoid policy and strategy.
Mr. Hoffman is the former Chair of the Massachusetts Cannabis Control Commission and a former partner at global management consulting firm Bain & Company. He also served as CEO of ThinkFire and Exchange Solutions and was the Executive Vice President and Chief Strategy Officer at Sapient. As Senior Vice President at CSC Index, he led the Chicago office and the Global Strategy Practice. Hoffman holds a BA in Economics from Wesleyan University and an MBA in Finance and Statistics from the University of Chicago.

Supply chain and quality.
Mr. Sheroff was Head of Supply Chain for large divisions within Johnson & Johnson, including Global Biologics and Janssen. Former WWVP of Quality at Warner Lambert (Pfizer) Mr. Sheroff is a supply-chain expert who has run multi-billion-dollar operations.

Business leadership.
Mr. Hammergren served as Chief Executive Officer and chairman of the Board of Directors of McKesson Corporation for nearly 20 years, retiring in 2019. Under his leadership, McKesson expanded its role in healthcare distribution and technology. He also held leadership roles at Kendall Healthcare and American Hospital Supply. He holds a BA from the University of Minnesota and an MBA from Xavier University. He also served on the board of Hewlett-Packard.

Finance.
John Schmid has over 35 years of experience in financial and senior management as well as a board member in the biotech industry and has raised over $900 million in private and public equity as well as debt financings as a Chief Financial Officer. He has taken two companies public as a CFO and over the past nine years, he has been involved in seven IPOs as an independent board member. He is a past President and a past board member of the San Diego Venture Group. Mr. Schmid received a BA in Economics from Wesleyan University and an MBA from the University of San Diego.

Early-stage investing.
Mr. Fleming has been founding, financing and operating breakthrough life science companies for over 35 years in the USA, Europe, Asia, and the Middle East. During his career he has raised more than $1 billion for early-stage investment funds that made more than 200 investments resulting in over 20 IPOs and 40 M&A events.